Related references
Note: Only part of the references are listed.Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Alessandra Metelli et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
Federico Nichetti et al.
CANCERS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Bleeding incidence and risk factors among cancer patients treated with anticoagulation
Dana E. Angelini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Myeloid cell-synthesized coagulation factor X dampens antitumor immunity
Claudine Graf et al.
SCIENCE IMMUNOLOGY (2019)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bleeding in cancer patients and its treatment: a review
Candice Johnstone et al.
ANNALS OF PALLIATIVE MEDICINE (2018)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
Gary H. Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
S. Kaatz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms
Joseph S. Palumbo et al.
BLOOD (2007)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
JS Palumbo et al.
BLOOD (2005)